Coronary artery disease is the biggest overall killer in women, although it is often viewed as a "male" disease. This book describes the gender-specific differences in the aetiology, clinical presentation, diagnosis, management and prevention of coronary disease in women and includes chapters on HRT, the menopause and oral contraception. Additionally, it offers practical advice for management of patients and has a strong focus on imaging, including nuclear imaging. Finally, the book includes a section on drugs that highlights gender-specific differences in pharmacologic treatment.
Coronary artery disease is the biggest overall killer in women, although it is often viewed as a "male" disease. This book describes the gender-specific differences in the aetiology, clinical presentation, diagnosis, management and prevention of coronary disease in women and includes chapters on HRT, the menopause and oral contraception. Additionally, it offers practical advice for management of patients and has a strong focus on imaging, including nuclear imaging. Finally, the book includes a section on drugs that highlights gender-specific differences in pharmacologic treatment.
Sprache
Verlagsort
Verlagsgruppe
Zielgruppe
Illustrationen
40 line illustrations, 25 halftones
Maße
Gewicht
ISBN-13
978-0-443-07960-3 (9780443079603)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Klassifikation
PART 1 EPIDEMIOLOGY, RISK FACTORS and PATHOPHYSIOLOGY: Chapter 1 Epidemiology of CHD in Women. International Trends in Morbidity and Mortality: Summary. Magnitude of the Problem. Trends in the UK, USA and Europe. Cross-Sectional Data. Longitudinal Data. Factors Influencing the Sex Mortality Differential. References Chapter 2 CHD Risk Factors in Women. Prevalence, Distribution and Predictive Value: Summary. Evidence from UK Studies. Data from International Studies. Gender Differences in Relative Predictive Value of Individual Risk Factor For: Lipoproteins (Cholesterol Triglycerides, HDL, LDL Etc). Apolipoprotein (A1 & B). Lp(A). Hypertension. Cigarette Smoking. Physical Inactivity. Obesity. Oral Contraception. Menopause. Oestrogen and HRT. Coagulation Factors. Eg Fibrinogen, Factor VII etc. Family History of CHD. Psychosocial Factors. Miscellaneous, Eg Stature etc. References Chapter 3 the Predictive Value of CHD Risk Factors in Women. Insights from the Framingham Heart Study Chapter 4 the Pathophysiology of CHD in Women: Summary. Gender Differences in Pathophysiology. Evidence from Animal Studies. Vascular Endothelium. Genetics and CHD in Women. References PART II CLINICAL PRESENTATION and DIAGNOSTIC TESTING for CHD in WOMEN: Chapter 5 Clinical Presentation of CHD in Women: Summary. Silent Ischaemia. Angina/Unstable Angina. Acute Myocardial Infarction. Silent Infarction. CHD in Pregnancy. Sudden Cardiac Death. Exercise and Sudden Death. References Chapter 6 Angina-Like Chest with Normal Coronary Angiograms in Women Chapter 7 Exercise Electrocardiography in Women Chapter 8 Ultrasound and Other Imaging Modalities: Summary. Echocardiography. Thallium Scintigraphy. CT/MRI/PET Chapter 9 Diagnostic Coronary Arteriography: Summary. Gender Specific Differences in Referral Patterns. Coronary Arteriography in Women. References PART III MANAGEMENT and PROGNOSIS of CHD in WOMEN: Chapter 10 C Oronary Disease in Women. Management and Prognosis: Summary. Acute Myocardial Infarction (Thrombolytic Etc). Angina/Unstable Angina. Cardiac Failure. References Chapter 11 Coronary Angioplasty (PTCA) in Women Chapter 12 Coronary Artery Surgery (CABG) in Women Chapter 13 Drugs and CHD in Women. Gender Specific Responses to Medication: Summary. B-Adrenergic Blocking Agents. Diuretics. Vasodilator. ACE Inhibitors. Calcium Channel Blocking Agents. Platelet Antagonists. Aspirin. References Chapter 14 the Management of Coronary Disease in Pregnancy PART IV the PREVENTION of CHD in WOMEN: Chapter 15 Primary Prevention: Summary. Interventions For: Ciagarette Smoking, Hypertension, Diabetes, Lipids, Exercise, Obesity. Oestrogen. Aspirin. The Magnitude of the Likely Benefit. Identifying Women at Risk Chapter 16 Hormone Replacement Therapy and Coronary Disease Chapter 17 Secondary Prevention: Summary. Cardiac Rehabilitation in Women. Regression of Atheroma. Aspirin. References Chapter 18 Preventing CHD in Women. Implications for Public Health Policy: Summaries. References
